The EUNCL provides critical infrastructure and characterisation services to qualify the selected nanoparticles' physical and chemical attributes, their in vitro biological properties, and their in vivo compatibility using animal models. The EU-NCL objective is to support and facilitate the regulatory review of your nanotechnologies that are intended for innovative therapies and diagnostics.
The EUNCL offers a comprehensive assay cascade aimed at evaluating the quality and safety of your nanomaterial. Moreover, the EUNCL will supply sponsors with a complete and detailed characterisation data set that enables researchers in academia, industry, and government to facilitate further development and translation of their nanotechnology strategies towards clinical applications.
The EUNCL characterisation platform aims to assess all categories of nanomedicines developed in EU.
EU-NCL call for access will accept continuous application with bi-annual review campaign in April and October each year.
EU-NCL call will accept all type of Med-NPs with putative application for treatment and/or diagnosis via injection or oral formulation.
If a project is selected, the EUNCL’s services will be provided at no cost to the submitting sponsor.
Guide for Applicants (PDF, 0.2 MB)
Non Disclusure Agreement (PDF, 0.2 MB)
European Nanomedicine Characterisation Laboratory (EU-NCL)